Skip to main content
Top
Published in: BMC Geriatrics 1/2021

Open Access 01-12-2021 | Tramadol | Research

Prevalence of potentially harmful multidrug interactions on medication lists of elderly ambulatory patients

Authors: Tara V. Anand, Brendan K. Wallace, Herbert S. Chase

Published in: BMC Geriatrics | Issue 1/2021

Login to get access

Abstract

Background

It has been hypothesized that polypharmacy may increase the frequency of multidrug interactions (MDIs) where one drug interacts with two or more other drugs, amplifying the risk of associated adverse drug events (ADEs). The main objective of this study was to determine the prevalence of MDIs in medication lists of elderly ambulatory patients and to identify the medications most commonly involved in MDIs that amplify the risk of ADEs.

Methods

Medication lists stored in the electronic health record (EHR) of 6,545 outpatients ≥60 years old were extracted from the enterprise data warehouse. Network analysis identified patients with three or more interacting medications from their medication lists. Potentially harmful interactions were identified from the enterprise drug-drug interaction alerting system. MDIs were considered to amplify the risk if interactions could increase the probability of ADEs.

Results

MDIs were identified in 1.3 % of the medication lists, the majority of which involved three interacting drugs (75.6 %) while the remainder involved four (15.6 %) or five or more (8.9 %) interacting drugs. The average number of medications on the lists was 3.1 ± 2.3 in patients with no drug interactions and 8.6 ± 3.4 in patients with MDIs. The prevalence of MDIs on medication lists was greater than 10 % in patients prescribed bupropion, tramadol, trazodone, cyclobenzaprine, fluoxetine, ondansetron, or quetiapine and greater than 20 % in patients prescribed amiodarone or methotrexate. All MDIs were potentially risk-amplifying due to pharmacodynamic interactions, where three or more medications were associated with the same ADE, or pharmacokinetic, where two or more drugs reduced the metabolism of a third drug. The most common drugs involved in MDIs were psychotropic, comprising 35.1 % of all drugs involved. The most common serious potential ADEs associated with the interactions were serotonin syndrome, seizures, prolonged QT interval and bleeding.

Conclusions

An identifiable number of medications, the majority of which are psychotropic, may be involved in MDIs in elderly ambulatory patients which may amplify the risk of serious ADEs. To mitigate the risk, providers will need to pay special attention to the overlapping drug-drug interactions which result in MDIs.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States from 1999-2012. JAMA. 2015;314(17):1818–30.PubMedPubMedCentralCrossRef Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States from 1999-2012. JAMA. 2015;314(17):1818–30.PubMedPubMedCentralCrossRef
3.
go back to reference Björkman IK. Drug-drug interactions in the elderly. The Annals of Pharmacotherapy. 2002;36(11):1675–81.PubMedCrossRef Björkman IK. Drug-drug interactions in the elderly. The Annals of Pharmacotherapy. 2002;36(11):1675–81.PubMedCrossRef
4.
go back to reference Sutherland JJ, Daly TM, Liu X, Goldstein K, Johnston JA, Ryan TP. Co-prescription trends in a large cohort of subjects predict substantial drug-drug interactions. PloS one. 2015;10(3):e0118991-e.CrossRef Sutherland JJ, Daly TM, Liu X, Goldstein K, Johnston JA, Ryan TP. Co-prescription trends in a large cohort of subjects predict substantial drug-drug interactions. PloS one. 2015;10(3):e0118991-e.CrossRef
5.
go back to reference Becker ML. Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiology and Drug Safety. 2007;16(6):641–51.PubMedCrossRef Becker ML. Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiology and Drug Safety. 2007;16(6):641–51.PubMedCrossRef
6.
go back to reference Hampton LM, Daubresse M, Chang H-Y, Alexander GC, Budnitz DS. Emergency Department Visits by Adults for Psychiatric Medication Adverse Events. JAMA Psychiatry. 2014;71(9):1006–14.PubMedPubMedCentralCrossRef Hampton LM, Daubresse M, Chang H-Y, Alexander GC, Budnitz DS. Emergency Department Visits by Adults for Psychiatric Medication Adverse Events. JAMA Psychiatry. 2014;71(9):1006–14.PubMedPubMedCentralCrossRef
7.
go back to reference Roughead EE. Multidrug interactions: the current clinical and pharmacovigilance challenge. Journal of Pharmacy Practice and Research. 2015;45(2):138–9.CrossRef Roughead EE. Multidrug interactions: the current clinical and pharmacovigilance challenge. Journal of Pharmacy Practice and Research. 2015;45(2):138–9.CrossRef
9.
go back to reference Tarjan R. Depth-First Search and Linear Graph Algorithms. SIAM Journal on Computing. 1972;1(2):146–60.CrossRef Tarjan R. Depth-First Search and Linear Graph Algorithms. SIAM Journal on Computing. 1972;1(2):146–60.CrossRef
11.
go back to reference Watanabe JH. Cost of Prescription Drug-Related Morbidity and Mortality. Ann Pharmacotherapy. 52(9):829–37. Watanabe JH. Cost of Prescription Drug-Related Morbidity and Mortality. Ann Pharmacotherapy. 52(9):829–37.
13.
go back to reference Aljadani R, Aseeri M. Prevalence of drug-drug interactions in geriatric patients at an ambulatory care pharmacy in a tertiary care teaching hospital. BMC Research Notes. 2018;11(1):234-.PubMedPubMedCentralCrossRef Aljadani R, Aseeri M. Prevalence of drug-drug interactions in geriatric patients at an ambulatory care pharmacy in a tertiary care teaching hospital. BMC Research Notes. 2018;11(1):234-.PubMedPubMedCentralCrossRef
14.
go back to reference Gandhi TK, Weingart SN, Borus J, Seger AC, Peterson J, Burdick E, et al. Adverse drug events in ambulatory care. NEJM. 2003;348(16):1556–64.PubMedCrossRef Gandhi TK, Weingart SN, Borus J, Seger AC, Peterson J, Burdick E, et al. Adverse drug events in ambulatory care. NEJM. 2003;348(16):1556–64.PubMedCrossRef
17.
go back to reference Obreli-Neto PR, Nobili A, de Oliveira Baldoni A, Guidoni CM, de Lyra Júnior DP, Pilger D, et al. Adverse drug reactions caused by drug–drug interactions in elderly outpatients: a prospective cohort study. Eur J Clin Pharmacol. 2012;68(12):1667–76.PubMedCrossRef Obreli-Neto PR, Nobili A, de Oliveira Baldoni A, Guidoni CM, de Lyra Júnior DP, Pilger D, et al. Adverse drug reactions caused by drug–drug interactions in elderly outpatients: a prospective cohort study. Eur J Clin Pharmacol. 2012;68(12):1667–76.PubMedCrossRef
18.
go back to reference Holm J, Eiermann B, Eliasson E, Mannheimer B. A limited number of prescribed drugs account for the great majority of drug-drug interactions. Eur J Clin Pharmacol. 2014;70(11):1375–83.PubMedCrossRef Holm J, Eiermann B, Eliasson E, Mannheimer B. A limited number of prescribed drugs account for the great majority of drug-drug interactions. Eur J Clin Pharmacol. 2014;70(11):1375–83.PubMedCrossRef
19.
go back to reference Létinier L, Cossin S, Mansiaux Y, Arnaud M, Salvo F, Bezin J, et al. Risk of Drug-Drug Interactions in Out-Hospital Drug Dispensings in France: Results From the DRUG-Drug Interaction Prevalence Study. Front Pharmacol. 2019;10(265). Létinier L, Cossin S, Mansiaux Y, Arnaud M, Salvo F, Bezin J, et al. Risk of Drug-Drug Interactions in Out-Hospital Drug Dispensings in France: Results From the DRUG-Drug Interaction Prevalence Study. Front Pharmacol. 2019;10(265).
20.
go back to reference Tulner LR. Drug-drug interactions in a geriatric outpatient cohort: prevalence and relevance. Drugs Aging. 2008;25(4):343–55.PubMedCrossRef Tulner LR. Drug-drug interactions in a geriatric outpatient cohort: prevalence and relevance. Drugs Aging. 2008;25(4):343–55.PubMedCrossRef
21.
go back to reference Jeon SM, Park S, Kim D, Kwon J-W. Risk of seizures associated with antipsychotic treatment in pediatrics with psychiatric disorders: a nested case–control study in Korea. European Child & Adolescent Psychiatry. 2021;30(3):391–9.CrossRef Jeon SM, Park S, Kim D, Kwon J-W. Risk of seizures associated with antipsychotic treatment in pediatrics with psychiatric disorders: a nested case–control study in Korea. European Child & Adolescent Psychiatry. 2021;30(3):391–9.CrossRef
22.
go back to reference Woosley RL, Heise CW, Gallo T, Tate J, Woosley D, Romero KA. QTdrugs List 822 Innovation Park Dr., Oro Valley, AZ 85755: AZCERT, Inc.; [Available from: www.CredibleMeds.org. Woosley RL, Heise CW, Gallo T, Tate J, Woosley D, Romero KA. QTdrugs List 822 Innovation Park Dr., Oro Valley, AZ 85755: AZCERT, Inc.; [Available from: www.CredibleMeds.org.
23.
go back to reference Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ: British Medical Journal. 2014;348:g1626.PubMedCrossRef Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ: British Medical Journal. 2014;348:g1626.PubMedCrossRef
24.
go back to reference Frommeyer G, Fischer C, Ellermann C, Dechering DG, Kochhäuser S, Lange PS, et al. Additive Proarrhythmic Effect of Combined Treatment with QT-Prolonging Agents. Cardiovascular Toxicology. 2018;18(1):84–90.PubMedCrossRef Frommeyer G, Fischer C, Ellermann C, Dechering DG, Kochhäuser S, Lange PS, et al. Additive Proarrhythmic Effect of Combined Treatment with QT-Prolonging Agents. Cardiovascular Toxicology. 2018;18(1):84–90.PubMedCrossRef
25.
go back to reference Isbister GK. The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment. Clinical neuropharmacology.28(5):205–14. Isbister GK. The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment. Clinical neuropharmacology.28(5):205–14.
26.
27.
go back to reference Chan TY. Adverse Interactions Between Warfarin and Nonsteroidal Antiinflammatory Drugs: Mechanisms, Clinical Significance, and Avoidance. Ann Pharmacother. 1995;29(12):1274–83.PubMedCrossRef Chan TY. Adverse Interactions Between Warfarin and Nonsteroidal Antiinflammatory Drugs: Mechanisms, Clinical Significance, and Avoidance. Ann Pharmacother. 1995;29(12):1274–83.PubMedCrossRef
28.
go back to reference Spina E, Santoro V, D’Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: An update. Clinical Therapeutics. 2008;30(7):1206–27.PubMedCrossRef Spina E, Santoro V, D’Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: An update. Clinical Therapeutics. 2008;30(7):1206–27.PubMedCrossRef
29.
go back to reference Hemeryck A. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Current Drug Metabolism. 2002;3(1):13–37.PubMedCrossRef Hemeryck A. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Current Drug Metabolism. 2002;3(1):13–37.PubMedCrossRef
30.
go back to reference Jeppesen U. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol. 1996;51(1):73–8.PubMedCrossRef Jeppesen U. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol. 1996;51(1):73–8.PubMedCrossRef
31.
go back to reference Kotlyar M. Inhibition of CYP2D6 activity by bupropion. Journal of Clinical Psychopharmacology. 2005;25(3):226–9.PubMedCrossRef Kotlyar M. Inhibition of CYP2D6 activity by bupropion. Journal of Clinical Psychopharmacology. 2005;25(3):226–9.PubMedCrossRef
32.
go back to reference Hesse LM. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug metabolism and disposition. 2000;28(10):1176–83.PubMed Hesse LM. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug metabolism and disposition. 2000;28(10):1176–83.PubMed
33.
go back to reference Boyce RD. Age-related changes in antidepressant pharmacokinetics and potential drug-drug interactions: a comparison of evidence-based literature and package insert information. The American journal of geriatric pharmacotherapy. 2012;10(2):139–50.PubMedPubMedCentralCrossRef Boyce RD. Age-related changes in antidepressant pharmacokinetics and potential drug-drug interactions: a comparison of evidence-based literature and package insert information. The American journal of geriatric pharmacotherapy. 2012;10(2):139–50.PubMedPubMedCentralCrossRef
34.
go back to reference Marusic S, Bacic-Vrca V, Obreli Neto PR, Franic M, Erdeljic V, Gojo-Tomic N. Actual drug–drug interactions in elderly patients discharged from internal medicine clinic: a prospective observational study. Eur J Clin Pharmacol. 2013;69(9):1717–24.PubMedCrossRef Marusic S, Bacic-Vrca V, Obreli Neto PR, Franic M, Erdeljic V, Gojo-Tomic N. Actual drug–drug interactions in elderly patients discharged from internal medicine clinic: a prospective observational study. Eur J Clin Pharmacol. 2013;69(9):1717–24.PubMedCrossRef
35.
go back to reference Sánchez-Fidalgo S, Guzmán-Ramos MI, Galván-Banqueri M, Bernabeu-Wittel M, Santos-Ramos B. Prevalence of drug interactions in elderly patients with multimorbidity in primary care. Int J Clin Pharm. 2017;39(2):343–53.PubMedCrossRef Sánchez-Fidalgo S, Guzmán-Ramos MI, Galván-Banqueri M, Bernabeu-Wittel M, Santos-Ramos B. Prevalence of drug interactions in elderly patients with multimorbidity in primary care. Int J Clin Pharm. 2017;39(2):343–53.PubMedCrossRef
36.
go back to reference Glassman PA. The utility of adding retrospective medication profiling to computerized provider order entry in an ambulatory care population. J Am Med Informatics Assoc. 14(4):424–31. Glassman PA. The utility of adding retrospective medication profiling to computerized provider order entry in an ambulatory care population. J Am Med Informatics Assoc. 14(4):424–31.
37.
go back to reference Leiss W, Méan M, Limacher A, Righini M, Jaeger K, Beer H-J, et al. Polypharmacy is Associated with an Increased Risk of Bleeding in Elderly Patients with Venous Thromboembolism. J Gen Intern Med. 2015;30(1):17–24.PubMedCrossRef Leiss W, Méan M, Limacher A, Righini M, Jaeger K, Beer H-J, et al. Polypharmacy is Associated with an Increased Risk of Bleeding in Elderly Patients with Venous Thromboembolism. J Gen Intern Med. 2015;30(1):17–24.PubMedCrossRef
38.
go back to reference Ray WA, Stein CM, Murray KT, Fuchs DC, Patrick SW, Daugherty J, et al. Association of Antipsychotic Treatment With Risk of Unexpected Death Among Children and Youths. JAMA Psychiatry. 2019;76(2):162–71.PubMedCrossRef Ray WA, Stein CM, Murray KT, Fuchs DC, Patrick SW, Daugherty J, et al. Association of Antipsychotic Treatment With Risk of Unexpected Death Among Children and Youths. JAMA Psychiatry. 2019;76(2):162–71.PubMedCrossRef
39.
go back to reference Danielsson B, Collin J, Jonasdottir Bergman G, Borg N, Salmi P, Fastbom J. Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults - a Swedish nationwide study. British journal of clinical pharmacology. 2016;81(4):773–83.PubMedPubMedCentralCrossRef Danielsson B, Collin J, Jonasdottir Bergman G, Borg N, Salmi P, Fastbom J. Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults - a Swedish nationwide study. British journal of clinical pharmacology. 2016;81(4):773–83.PubMedPubMedCentralCrossRef
41.
go back to reference Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death. NEJM. 2009;360(3):225–35.PubMedCrossRef Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death. NEJM. 2009;360(3):225–35.PubMedCrossRef
42.
go back to reference Schneeweiss S, Avorn J. Antipsychotic Agents and Sudden Cardiac Death — How Should We Manage the Risk? NEJM. 2009;360(3):294–6. Schneeweiss S, Avorn J. Antipsychotic Agents and Sudden Cardiac Death — How Should We Manage the Risk? NEJM. 2009;360(3):294–6.
43.
go back to reference Risgaard B. Sudden cardiac death in young adults with previous hospital-based psychiatric inpatient and outpatient treatment: a nationwide cohort study from Denmark. The Journal of Clinical Psychiatry. 2015;76(9):e1122-9.PubMedCrossRef Risgaard B. Sudden cardiac death in young adults with previous hospital-based psychiatric inpatient and outpatient treatment: a nationwide cohort study from Denmark. The Journal of Clinical Psychiatry. 2015;76(9):e1122-9.PubMedCrossRef
44.
go back to reference Simpson TF, Salazar JW, Vittinghoff E, Probert J, Iwahashi A, Olgin JE, et al. Association of QT-Prolonging Medications With Risk of Autopsy-Defined Causes of Sudden Death. JAMA Internal Medicine. 2020. Simpson TF, Salazar JW, Vittinghoff E, Probert J, Iwahashi A, Olgin JE, et al. Association of QT-Prolonging Medications With Risk of Autopsy-Defined Causes of Sudden Death. JAMA Internal Medicine. 2020.
45.
go back to reference Zhu J, Hou W, Xu Y, Ji F, Wang G, Chen C, et al. Antipsychotic drugs and sudden cardiac death: A literature review of the challenges in the prediction, management, and future steps. Psychiatry Research. 2019;281:112598.PubMedCrossRef Zhu J, Hou W, Xu Y, Ji F, Wang G, Chen C, et al. Antipsychotic drugs and sudden cardiac death: A literature review of the challenges in the prediction, management, and future steps. Psychiatry Research. 2019;281:112598.PubMedCrossRef
46.
go back to reference Xiang Y, Albin A, Ren K, Zhang P, Etter JP, Lin S, et al. Efficiently mining Adverse Event Reporting System for multiple drug interactions. AMIA Joint Summits on Translational Science proceedings AMIA Joint Summits on Translational Science. 2014;2014:120-5. Xiang Y, Albin A, Ren K, Zhang P, Etter JP, Lin S, et al. Efficiently mining Adverse Event Reporting System for multiple drug interactions. AMIA Joint Summits on Translational Science proceedings AMIA Joint Summits on Translational Science. 2014;2014:120-5.
47.
go back to reference Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Can Pharm J (Ott). 2016;149(3):139–52.CrossRef Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Can Pharm J (Ott). 2016;149(3):139–52.CrossRef
48.
go back to reference Yamreudeewong W, DeBisschop M, Martin LG, Lower DL. Potentially Significant Drug Interactions of Class III Antiarrhythmic Drugs. Drug Safety. 2003;26(6):421–38.PubMedCrossRef Yamreudeewong W, DeBisschop M, Martin LG, Lower DL. Potentially Significant Drug Interactions of Class III Antiarrhythmic Drugs. Drug Safety. 2003;26(6):421–38.PubMedCrossRef
49.
go back to reference Slight SP, Seger DL, Franz C, Wong A, Bates DW. The national cost of adverse drug events resulting from inappropriate medication-related alert overrides in the United States. J Am Med Inform Assoc. 2018;25(9):1183–8.PubMedPubMedCentralCrossRef Slight SP, Seger DL, Franz C, Wong A, Bates DW. The national cost of adverse drug events resulting from inappropriate medication-related alert overrides in the United States. J Am Med Inform Assoc. 2018;25(9):1183–8.PubMedPubMedCentralCrossRef
50.
go back to reference Phansalkar S. Drug-drug interactions that should be non-interruptive in order to reduce alert fatigue in electronic health records. Journal of the American Medical Informatics Association: JAMIA. 2013;20(3):489–93. Phansalkar S. Drug-drug interactions that should be non-interruptive in order to reduce alert fatigue in electronic health records. Journal of the American Medical Informatics Association: JAMIA. 2013;20(3):489–93.
51.
go back to reference Hanlon JT, Semla TP, Schmader KE. Alternative Medications for Medications in the Use of High-Risk Medications in the Elderly and Potentially Harmful Drug–Disease Interactions in the Elderly Quality Measures. Journal of the American Geriatrics Society. 2015;63(12):e8-e18.PubMedPubMedCentralCrossRef Hanlon JT, Semla TP, Schmader KE. Alternative Medications for Medications in the Use of High-Risk Medications in the Elderly and Potentially Harmful Drug–Disease Interactions in the Elderly Quality Measures. Journal of the American Geriatrics Society. 2015;63(12):e8-e18.PubMedPubMedCentralCrossRef
54.
go back to reference Furyk JS, Meek RA, Egerton-Warburton D. Drugs for the treatment of nausea and vomiting in adults in the emergency department setting. The Cochrane database of systematic reviews. 2015;2015(9):CD010106-CD. Furyk JS, Meek RA, Egerton-Warburton D. Drugs for the treatment of nausea and vomiting in adults in the emergency department setting. The Cochrane database of systematic reviews. 2015;2015(9):CD010106-CD.
55.
56.
go back to reference Mojtabai R, Olfson M. National Trends in Psychotropic Medication Polypharmacy in Office-Based Psychiatry. Archives of General Psychiatry. 2010;67(1):26–36.PubMedCrossRef Mojtabai R, Olfson M. National Trends in Psychotropic Medication Polypharmacy in Office-Based Psychiatry. Archives of General Psychiatry. 2010;67(1):26–36.PubMedCrossRef
57.
go back to reference Kok RM, Reynolds CF, III. Management of Depression in Older Adults: A Review. JAMA. 2017;317(20):2114–22.PubMedCrossRef Kok RM, Reynolds CF, III. Management of Depression in Older Adults: A Review. JAMA. 2017;317(20):2114–22.PubMedCrossRef
58.
go back to reference Brooks JO, Hoblyn JC. Neurocognitive Costs and Benefits of Psychotropic Medications in Older Adults. Journal of Geriatric Psychiatry and Neurology. 2007;20(4):199–214.PubMedCrossRef Brooks JO, Hoblyn JC. Neurocognitive Costs and Benefits of Psychotropic Medications in Older Adults. Journal of Geriatric Psychiatry and Neurology. 2007;20(4):199–214.PubMedCrossRef
59.
go back to reference Petit-Monéger A, Jouhet V, Thiessard F, Berdaï D, Noize P, Gilleron V, et al. Appropriateness of psychotropic drug prescriptions in the elderly: structuring tools based on data extracted from the hospital information system to understand physician practices. BMC Health Services Research. 2019;19(1):272.PubMedPubMedCentralCrossRef Petit-Monéger A, Jouhet V, Thiessard F, Berdaï D, Noize P, Gilleron V, et al. Appropriateness of psychotropic drug prescriptions in the elderly: structuring tools based on data extracted from the hospital information system to understand physician practices. BMC Health Services Research. 2019;19(1):272.PubMedPubMedCentralCrossRef
60.
go back to reference Leung GM, Johnston JM, Tin KYK, Wong IOL, Ho L-M, Lam WWT, et al. Randomised controlled trial of clinical decision support tools to improve learning of evidence based medicine in medical students. BMJ. 2003;327:1090–5.PubMedPubMedCentralCrossRef Leung GM, Johnston JM, Tin KYK, Wong IOL, Ho L-M, Lam WWT, et al. Randomised controlled trial of clinical decision support tools to improve learning of evidence based medicine in medical students. BMJ. 2003;327:1090–5.PubMedPubMedCentralCrossRef
61.
go back to reference Nauta KJ, Groenhof F, Schuling J, Hugtenburg JG, van Hout HPJ, Haaijer-Ruskamp FM, et al. Application of the STOPP/START criteria to a medical record database. Pharmacoepidemiol Drug Saf. 2017;26(10):1242–7.PubMedCrossRef Nauta KJ, Groenhof F, Schuling J, Hugtenburg JG, van Hout HPJ, Haaijer-Ruskamp FM, et al. Application of the STOPP/START criteria to a medical record database. Pharmacoepidemiol Drug Saf. 2017;26(10):1242–7.PubMedCrossRef
62.
64.
go back to reference Steinert T. Epileptic Seizures Under Antidepressive Drug Treatment: Systematic Review. Pharmacopsychiatry. 2017;51(4):121–35.PubMed Steinert T. Epileptic Seizures Under Antidepressive Drug Treatment: Systematic Review. Pharmacopsychiatry. 2017;51(4):121–35.PubMed
65.
go back to reference Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ. 2011;343:d4551.PubMedPubMedCentralCrossRef Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ. 2011;343:d4551.PubMedPubMedCentralCrossRef
66.
go back to reference Cipriani A. Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis. Focus (American Psychiatric Publishing). 2018;16(4):420–9.PubMedCentral Cipriani A. Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis. Focus (American Psychiatric Publishing). 2018;16(4):420–9.PubMedCentral
67.
go back to reference Ong M-S, Olson KL, Chadwick L, Liu C, Mandl KD. The Impact of Provider Networks on the Co-Prescriptions of Interacting Drugs: A Claims-Based Analysis. Drug safety. 2017;40(3):263–72.PubMedPubMedCentralCrossRef Ong M-S, Olson KL, Chadwick L, Liu C, Mandl KD. The Impact of Provider Networks on the Co-Prescriptions of Interacting Drugs: A Claims-Based Analysis. Drug safety. 2017;40(3):263–72.PubMedPubMedCentralCrossRef
68.
go back to reference Olvey EL, Clauschee S, Malone DC. Comparison of Critical Drug–Drug Interaction Listings: The Department of Veterans Affairs Medical System and Standard Reference Compendia. Clinical Pharmacology & Therapeutics. 2010;87(1):48–51.CrossRef Olvey EL, Clauschee S, Malone DC. Comparison of Critical Drug–Drug Interaction Listings: The Department of Veterans Affairs Medical System and Standard Reference Compendia. Clinical Pharmacology & Therapeutics. 2010;87(1):48–51.CrossRef
70.
go back to reference Ayvaz S, Horn J, Hassanzadeh O, Zhu Q, Stan J, Tatonetti NP, et al. Toward a complete dataset of drug–drug interaction information from publicly available sources. J Biomed Inform. 2015;55:206–17.PubMedPubMedCentralCrossRef Ayvaz S, Horn J, Hassanzadeh O, Zhu Q, Stan J, Tatonetti NP, et al. Toward a complete dataset of drug–drug interaction information from publicly available sources. J Biomed Inform. 2015;55:206–17.PubMedPubMedCentralCrossRef
71.
go back to reference Muhič N, Mrhar A, Brvar M. Comparative analysis of three drug–drug interaction screening systems against probable clinically relevant drug–drug interactions: a prospective cohort study. Eur J Clin Pharmacol. 2017;73(7):875–82.PubMedCrossRef Muhič N, Mrhar A, Brvar M. Comparative analysis of three drug–drug interaction screening systems against probable clinically relevant drug–drug interactions: a prospective cohort study. Eur J Clin Pharmacol. 2017;73(7):875–82.PubMedCrossRef
72.
go back to reference Fung KW, Kapusnik-Uner J, Cunningham J, Higby-Baker S, Bodenreider O. Comparison of three commercial knowledge bases for detection of drug-drug interactions in clinical decision support. J Am Med Inform Assoc. 2017;24(4):806–12.PubMedPubMedCentralCrossRef Fung KW, Kapusnik-Uner J, Cunningham J, Higby-Baker S, Bodenreider O. Comparison of three commercial knowledge bases for detection of drug-drug interactions in clinical decision support. J Am Med Inform Assoc. 2017;24(4):806–12.PubMedPubMedCentralCrossRef
73.
go back to reference Cornu P. High-priority and low-priority drug-drug interactions in different international electronic health record systems: A comparative study. International journal of medical informatics (Shannon, Ireland). 2018;111:165–71.CrossRef Cornu P. High-priority and low-priority drug-drug interactions in different international electronic health record systems: A comparative study. International journal of medical informatics (Shannon, Ireland). 2018;111:165–71.CrossRef
74.
go back to reference Tatonetti NP, Denny JC, Murphy SN, Fernald GH, Krishnan G, Castro V, et al. Detecting Drug Interactions From Adverse-Event Reports: Interaction Between Paroxetine and Pravastatin Increases Blood Glucose Levels. Clinical Pharmacology & Therapeutics. 2011;90(1):133–42.CrossRef Tatonetti NP, Denny JC, Murphy SN, Fernald GH, Krishnan G, Castro V, et al. Detecting Drug Interactions From Adverse-Event Reports: Interaction Between Paroxetine and Pravastatin Increases Blood Glucose Levels. Clinical Pharmacology & Therapeutics. 2011;90(1):133–42.CrossRef
75.
go back to reference Lorberbaum T, Sampson KJ, Chang JB, Iyer V, Woosley RL, Kass RS, et al. Coupling Data Mining and Laboratory Experiments to Discover Drug Interactions Causing QT Prolongation. J Am Coll Cardiol. 2016;68(16):1756–64. Lorberbaum T, Sampson KJ, Chang JB, Iyer V, Woosley RL, Kass RS, et al. Coupling Data Mining and Laboratory Experiments to Discover Drug Interactions Causing QT Prolongation. J Am Coll Cardiol. 2016;68(16):1756–64.
76.
go back to reference Lorberbaum T, Sampson KJ, Woosley RL, Kass RS, Tatonetti NP. An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval. Drug Saf. 2016;39(5):433–41.PubMedPubMedCentralCrossRef Lorberbaum T, Sampson KJ, Woosley RL, Kass RS, Tatonetti NP. An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval. Drug Saf. 2016;39(5):433–41.PubMedPubMedCentralCrossRef
Metadata
Title
Prevalence of potentially harmful multidrug interactions on medication lists of elderly ambulatory patients
Authors
Tara V. Anand
Brendan K. Wallace
Herbert S. Chase
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Geriatrics / Issue 1/2021
Electronic ISSN: 1471-2318
DOI
https://doi.org/10.1186/s12877-021-02594-z

Other articles of this Issue 1/2021

BMC Geriatrics 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.